Osimertinib is effective against the T790M mutation and markedly improves survival outcomes for patients with advanced-stage EGFR-mutated NSCLC, especially for lung adenocarcinoma (LUAD), in whom previous regimens have failed [3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.